ICU Medical, Inc. (NASDAQ:ICUI) Given Consensus Recommendation of “Buy” by Brokerages

ICU Medical, Inc. (NASDAQ:ICUI) has earned an average recommendation of “Buy” from the nine research firms that are presently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a hold rating, four have given a buy rating and three have issued a strong buy rating on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $172.00.

A number of brokerages have recently commented on ICUI. Sanford C. Bernstein lowered shares of ICU Medical to a “market perform” rating in a research report on Monday, June 15th. Jefferies Financial Group upgraded shares of ICU Medical to a “strong-buy” rating in a report on Thursday, May 7th. Needham & Company LLC raised shares of ICU Medical from a “hold” rating to a “buy” rating and set a $165.00 target price for the company in a research report on Wednesday, May 27th. BTIG Research began coverage on shares of ICU Medical in a research note on Monday, June 15th. They issued a “buy” rating and a $170.00 price target on the stock. Finally, KeyCorp boosted their price target on shares of ICU Medical from $164.00 to $182.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 21st.

ICU Medical Price Performance

NASDAQ:ICUI opened at $157.44 on Wednesday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.17 and a current ratio of 2.34. The company has a market cap of $3.93 billion, a PE ratio of 85.10, a PEG ratio of 2.20 and a beta of 0.76. ICU Medical has a 52-week low of $107.00 and a 52-week high of $162.85. The stock has a 50-day simple moving average of $144.21 and a 200 day simple moving average of $139.71.

ICU Medical (NASDAQ:ICUI) last released its earnings results on Thursday, May 7th. The medical instruments supplier reported $1.97 EPS for the quarter, beating the consensus estimate of $1.78 by $0.19. ICU Medical had a return on equity of 7.50% and a net margin of 2.15%.The firm had revenue of $525.77 million for the quarter, compared to analysts’ expectations of $520.65 million. During the same quarter in the previous year, the business posted $1.72 EPS. The business’s quarterly revenue was down 12.3% compared to the same quarter last year. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. On average, sell-side analysts expect that ICU Medical will post 6.51 EPS for the current fiscal year.

Insider Activity

In related news, VP Virginia Ruth Sanzone sold 2,447 shares of the stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $124.08, for a total transaction of $303,623.76. Following the completion of the transaction, the vice president directly owned 19,460 shares of the company’s stock, valued at approximately $2,414,596.80. This represents a 11.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director David C. Greenberg sold 2,424 shares of the firm’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $122.91, for a total value of $297,933.84. Following the completion of the transaction, the director owned 7,960 shares of the company’s stock, valued at approximately $978,363.60. This represents a 23.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 2.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On ICU Medical

Several large investors have recently made changes to their positions in ICUI. Hilton Head Capital Partners LLC bought a new stake in ICU Medical during the fourth quarter worth $32,000. Covestor Ltd lifted its stake in ICU Medical by 22.1% in the fourth quarter. Covestor Ltd now owns 696 shares of the medical instruments supplier’s stock valued at $99,000 after acquiring an additional 126 shares during the last quarter. Strs Ohio grew its position in shares of ICU Medical by 60.0% in the 4th quarter. Strs Ohio now owns 800 shares of the medical instruments supplier’s stock valued at $114,000 after acquiring an additional 300 shares during the period. Rockefeller Capital Management L.P. grew its position in shares of ICU Medical by 21.6% in the 4th quarter. Rockefeller Capital Management L.P. now owns 823 shares of the medical instruments supplier’s stock valued at $117,000 after acquiring an additional 146 shares during the period. Finally, Kemnay Advisory Services Inc. acquired a new position in shares of ICU Medical during the 4th quarter worth about $120,000. Institutional investors and hedge funds own 96.10% of the company’s stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.